UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ____________ to___________
Commission File Number
(Exact name of registrant as specified in its charter)
|
||
(State or other jurisdiction of |
|
(I.R.S. Employer Identification No.) |
incorporation or organization) |
|
|
|
|
|
|
||
(Address of principal executive office) |
|
(Zip Code) |
(
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
|
☒ |
|
No |
|
|
|
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
|
☒ |
|
|
No |
|
|
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
☒ |
|
Accelerated filer |
☐ |
|
Non-accelerated filer |
☐ |
|
Smaller reporting company |
||
Emerging growth company |
|
|
|
|
|
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes |
|
|
|
No |
|
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol |
|
Name of each exchange on which registered |
|
|
As of April 26, 2024, the latest practicable date, the registrant had
EXPONENT, INC.
FORM 10-Q
TABLE OF CONTENTS
|
|
|
|
Page |
|
|
|
|
|
|
3 |
|||
|
|
|
|
|
Item 1. |
|
|
3 |
|
|
|
|
|
|
|
|
Condensed Consolidated Balance Sheets as of March 29, 2024 and December 29, 2023 |
|
3 |
|
|
|
|
|
|
|
|
4 |
|
|
|
|
|
|
|
|
|
5 |
|
|
|
|
|
|
|
|
|
6 |
|
|
|
|
|
|
|
|
|
7 |
|
|
|
|
|
|
|
|
Notes to Unaudited Condensed Consolidated Financial Statements |
|
8 |
|
|
|
|
|
Item 2. |
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
|
19 |
|
|
|
|
|
Item 3. |
|
|
26 |
|
|
|
|
|
|
Item 4. |
|
|
26 |
|
|
|
|
|
|
|
27 |
|||
|
|
|
|
|
Item 1. |
|
|
27 |
|
|
|
|
|
|
Item 1A. |
|
|
27 |
|
|
|
|
|
|
Item 2. |
|
|
27 |
|
|
|
|
|
|
Item 3. |
|
|
27 |
|
|
|
|
|
|
Item 4. |
|
|
27 |
|
|
|
|
|
|
Item 5. |
|
|
27 |
|
|
|
|
|
|
Item 6. |
|
|
29 |
|
|
|
|
|
|
|
|
|
30 |
|
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements
EXPONENT, INC.
Condensed Consolidated Balance Sheets
March 29, 2024 and December 29, 2023
(in thousands, except par value)
(unaudited)
|
|
March 29, |
|
|
December 29, |
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
|
|
$ |
|
||
Accounts receivable, net of allowance for contract losses and doubtful accounts |
|
|
|
|
|
|
||
Prepaid expenses and other current assets |
|
|
|
|
|
|
||
Total current assets |
|
|
|
|
|
|
||
|
|
|
|
|
|
|
||
Property, equipment and leasehold improvements, net of accumulated depreciation and |
|
|
|
|
|
|
||
Operating lease right-of-use assets |
|
|
|
|
|
|
||
Goodwill |
|
|
|
|
|
|
||
Deferred income taxes |
|
|
|
|
|
|
||
Deferred compensation plan assets |
|
|
|
|
|
|
||
Other assets |
|
|
|
|
|
|
||
Total assets |
|
$ |
|
|
$ |
|
||
|
|
|
|
|
|
|
||
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable and accrued liabilities |
|
$ |
|
|
$ |
|
||
Accrued payroll and employee benefits |
|
|
|
|
|
|
||
Deferred revenues |
|
|
|
|
|
|
||
Operating lease liabilities |
|
|
|
|
|
|
||
Total current liabilities |
|
|
|
|
|
|
||
|
|
|
|
|
|
|
||
Other liabilities |
|
|
|
|
|
|
||
Deferred compensation plan liabilities |
|
|
|
|
|
|
||
Operating lease liabilities |
|
|
|
|
|
|
||
Total liabilities |
|
|
|
|
|
|
||
Stockholders’ equity: |
|
|
|
|
|
|
||
Common stock, $ |
|
|
|
|
|
|
||
Additional paid-in capital |
|
|
|
|
|
|
||
Accumulated other comprehensive loss |
|
|
|
|
|
|
||
Foreign currency translation adjustments |
|
|
( |
) |
|
|
( |
) |
Retained earnings |
|
|
|
|
|
|
||
Treasury stock, at cost; |
|
|
( |
) |
|
|
( |
) |
Total stockholders’ equity |
|
|
|
|
|
|
||
Total liabilities and stockholders’ equity |
|
$ |
|
|
$ |
|
||
The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.
- 3 -
EXPONENT, INC.
Condensed Consolidated Statements of Income
For the Three Months Ended March 29, 2024 and March 31, 2023
(in thousands, except per share data)
(unaudited)
|
|
Three Months Ended |
|
|||||
|
|
March 29, |
|
|
March 31, |
|
||
Revenues: |
|
|
|
|
|
|
||
Revenues before reimbursements |
|
$ |
|
|
$ |
|
||
Reimbursements |
|
|
|
|
|
|
||
Revenues |
|
|
|
|
|
|
||
Operating expenses: |
|
|
|
|
|
|
||
Compensation and related expenses |
|
|
|
|
|
|
||
Other operating expenses |
|
|
|
|
|
|
||
Reimbursable expenses |
|
|
|
|
|
|
||
General and administrative expenses |
|
|
|
|
|
|
||
Total operating expenses |
|
|
|
|
|
|
||
Operating income |
|
|
|
|
|
|
||
Other income, net: |
|
|
|
|
|
|
||
Interest income, net |
|
|
|
|
|
|
||
Miscellaneous income (loss), net |
|
|
|
|
|
|
||
Total other income (loss), net |
|
|
|
|
|
|
||
Income before income taxes |
|
|
|
|
|
|
||
Income taxes |
|
|
|
|
|
|
||
Net income |
|
$ |
|
|
$ |
|
||
Net income per share: |
|
|
|
|
|
|
||
Basic |
|
$ |
|
|
$ |
|
||
Diluted |
|
$ |
|
|
$ |
|
||
Shares used in per share computations: |
|
|
|
|
|
|
||
Basic |
|
|
|
|
|
|
||
Diluted |
|
|
|
|
|
|
||
Cash dividends declared per common share |
|
$ |
|
|
$ |
|
||
The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.
- 4 -
EXPONENT, INC.
Condensed Consolidated Statements of Comprehensive Income
For the Three Months Ended March 29, 2024 and March 31, 2023
(in thousands)
(unaudited)
|
|
Three Months Ended |
|
|||||
|
|
March 29, |
|
|
March 31, |
|
||
Net income |
|
$ |
|
|
$ |
|
||
Other comprehensive income (loss): |
|
|
|
|
|
|
||
Foreign currency translation |
|
|
( |
) |
|
|
|
|
Comprehensive income |
|
$ |
|
|
$ |
|
||
The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.
- 5 -
EXPONENT, INC
Condensed Consolidated Statements of Stockholders’ Equity
For the Three Months Ended March 29, 2024 and March 31, 2023
(in thousands)
(unaudited)
|
|
Three Months Ended March 29, 2024 |
|
|||||||||||||||||||||||||||||
|
|
Common Stock |
|
|
Additional |
|
|
Accumulated |
|
|
Retained |
|
|
Treasury Stock |
|
|
|
|
||||||||||||||
|
|
Shares |
|
|
Amount |
|
|
capital |
|
|
loss |
|
|
earnings |
|
|
Shares |
|
|
Amount |
|
|
Total |
|
||||||||
Balance at December 29, 2023 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|
|
|
|
$ |
( |
) |
|
$ |
|
||||||
Employee stock purchase plan |
|
|
- |
|
|
|
- |
|
|
|
|
|
|
- |
|
|
|
- |
|
|
|
( |
) |
|
|
|
|
|
|
|||
Amortization of unrecognized stock-based |
|
|
- |
|
|
|
- |
|
|
|
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
||
Purchase of treasury shares |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
( |
) |
|
|
( |
) |
|
Foreign currency translation adjustments |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
( |
) |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
( |
) |
Grant of restricted stock units to settle accrued |
|
|
- |
|
|
|
- |
|
|
|
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
||
Settlement of restricted stock units |
|
|
- |
|
|
|
- |
|
|
|
( |
) |
|
|
- |
|
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Exercise of stock options |
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|||||
Dividends and dividend equivalent rights |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
( |
) |
|
|
- |
|
|
|
- |
|
|
|
( |
) |
Net income |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
- |
|
|
|
- |
|
|
|
|
||
Balance at March 29, 2024 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|
|
|
|
$ |
( |
) |
|
$ |
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
|
Three Months Ended March 31, 2023 |
|
|||||||||||||||||||||||||||||
|
|
Common Stock |
|
|
Additional |
|
|
Accumulated |
|
|
Retained |
|
|
Treasury Stock |
|
|
|
|
||||||||||||||
(In thousands) |
|
Shares |
|
|
Amount |
|
|
capital |
|
|
income (loss) |
|
|
earnings |
|
|
Shares |
|
|
Amount |
|
|
Total |
|
||||||||
Balance at December 30, 2022 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|
|
|
|
$ |
( |
) |
|
$ |
|
||||||
Employee stock purchase plan |
|
|
- |
|
|
|
- |
|
|
|
|
|
|
- |
|
|
|
- |
|
|
|
( |
) |
|
|
|
|
|
|
|||
Amortization of unrecognized stock-based |
|
|
- |
|
|
|
- |
|
|
|
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
||
Foreign currency translation adjustments |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
||
Grant of restricted stock units to settle accrued |
|
|
- |
|
|
|
- |
|
|
|
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
||
Settlement of restricted stock units |
|
|
- |
|
|
|
- |
|
|
|
( |
) |
|
|
- |
|
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Exercise of stock options |
|
|
- |
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|
|
|
|||||
Dividends and dividend equivalent rights |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
( |
) |
|
|
- |
|
|
|
- |
|
|
|
( |
) |
Net income |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
|
|
|
- |
|
|
|
- |
|
|
|
|
||
Balance at March 31, 2023 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
||||||
The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.
- 6 -
EXPONENT, INC.
Condensed Consolidated Statements of Cash Flows
For the Three Months Ended March 29, 2024 and March 31, 2023
(in thousands)
(unaudited)
|
|
Three Months Ended |
|
|||||
|
|
March 29, |
|
|
March 31, |
|
||
Cash flows from operating activities: |
|
|
|
|
|
|
||
Net income |
|
$ |
|
|
$ |
|
||
Adjustments to reconcile net income to net cash used in |
|
|
|
|
|
|
||
Depreciation and amortization of property, equipment and |
|
|
|
|
|
|
||
Provision for contract losses and doubtful accounts |
|
|
|
|
|
|
||
Stock-based compensation |
|
|
|
|
|
|
||
Deferred income tax provision |
|
|
|
|
|
|
||
Changes in operating assets and liabilities: |
|
|
|
|
|
|
||
Accounts receivable |
|
|
|
|
|
( |
) |
|
Prepaid expenses and other current assets |
|
|
( |
) |
|
|
( |
) |
Change in operating leases |
|
|
( |
) |
|
|
( |
) |
Accounts payable and accrued liabilities |
|
|
|
|
|
( |
) |
|
Accrued payroll and employee benefits |
|
|
( |
) |
|
|
( |
) |
Deferred revenues |
|
|
( |
) |
|
|
( |
) |
Net cash provided by (used in) operating activities |
|
|
|
|
|
( |
) |
|
Cash flows from investing activities: |
|
|
|
|
|
|
||
Capital expenditures |
|
|
( |
) |
|
|
( |
) |
Net cash used in investing activities |
|
|
( |
) |
|
|
( |
) |
Cash flows from financing activities: |
|
|
|
|
|
|
||
Payroll taxes for restricted stock units |
|
|
( |
) |
|
|
( |
) |
Repurchase of common stock |
|
|
( |
) |
|
|
- |
|
Exercise of stock-based payment awards |
|
|
|
|
|
|
||
Dividends and dividend equivalents rights |
|
|
( |
) |
|
|
( |
) |
Net cash used in financing activities |
|
|
( |
) |
|
|
( |
) |
Effect of foreign currency exchange rates on cash and cash equivalents |
|
|
( |
) |
|
|
|
|
Net decrease in cash and cash equivalents |
|
|
( |
) |
|
|
( |
) |
Cash and cash equivalents at beginning of period |
|
|
|
|
|
|
||
Cash and cash equivalents at end of period |
|
$ |
|
|
$ |
|
||
The accompanying notes are an integral part of these Unaudited Condensed Consolidated Financial Statements.
- 7 -
EXPONENT, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Note 1:
Exponent, Inc. (referred to as the “Company” or “Exponent”) is an engineering and scientific consulting firm that provides solutions to complex problems. The Company operates on a 52-53 week fiscal year ending on the Friday closest to the last day of December.
The accompanying unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information, the instructions to Form 10-Q and Article 10 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission. Accordingly, they do not contain all the information and notes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments which are necessary for the fair presentation of the condensed consolidated financial statements have been included and all such adjustments are of a normal and recurring nature. The operating results for the three months ended March 29, 2024 are not necessarily representative of the results of future quarterly or annual periods. The following information should be read in conjunction with the audited consolidated financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2023, which was filed with the U.S. Securities and Exchange Commission on February 23, 2024 and amended on April 17, 2024.
The unaudited condensed consolidated financial statements include the accounts of Exponent, Inc. and its subsidiaries, which are all wholly owned. All intercompany accounts and transactions have been eliminated in consolidation.
Note 2: Revenue Recognition
Substantially all of the Company’s engagements are performed under time and materials or fixed-price arrangements. For time and materials contracts, the Company utilizes the practical expedient under Accounting Standards Codification 606 – Revenue from Contracts with Customers, which states that if an entity has a right to consideration from a customer in an amount that corresponds directly with the value of the entity’s performance completed to date (for example, a service contract in which an entity bills a fixed amount for each hour of service provided) then the entity may recognize revenue in the amount to which the entity has a right to invoice.
The following table discloses the percentage of the Company’s revenue generated from time and materials contracts:
|
|
Three Months Ended |
|
|||||
|
|
March 29, |
|
|
March 31, |
|
||
Engineering & other scientific |
|
|
% |
|
|
% |
||
Environmental and health |
|
|
% |
|
|
% |
||
Total time and materials revenues |
|
|
% |
|
|
% |
||
|
|
|
|
|
|
|
||
- 8 -
For fixed-price contracts, the Company recognizes revenue over time because of the continuous transfer of control to the customer. The customer typically controls the work in process as evidenced either by contractual termination clauses or by the Company’s rights to payment for work performed to date to deliver services that do not have an alternative use to the Company. Revenue for fixed-price contracts is recognized based on the relationship of incurred labor hours at standard rates to the Company’s estimate of the total labor hours at standard rates it expects to incur over the term of the contract. The Company believes this methodology achieves a reliable measure of the revenue from the consulting services it provides to its customers under fixed-price contracts given the nature of the consulting services the Company provides.
The following table discloses the percentage of the Company’s revenue generated from fixed price contracts:
|
|
Three Months Ended |
|
|||||
|
|
March 29, |
|
|
March 31, |
|
||
Engineering & other scientific |
|
|
% |
|
|
% |
||
Environmental and health |
|
|
% |
|
|
% |
||
Total fixed price revenues |
|
|
% |
|
|
% |
||
|
|
|
|
|
|
|
||
Deferred revenues represent amounts billed to clients in advance of services provided. During the first quarter of 2024, $
Reimbursements, including those related to travel and other out-of-pocket expenses, and other similar third- party costs such as the cost of materials and certain subcontracts, are included in revenues, and an equivalent amount of reimbursable expenses are included in operating expenses. Any mark-up on reimbursable expenses is included in revenues before reimbursements. The Company reports revenues net of subcontractor fees for certain subcontracts where the Company has determined that it is acting as an agent because its performance obligation is to arrange for the provision of goods or services by another party. The total amount of subcontractor fees not included in revenues because the Company was acting as an agent were $
- 9 -
Note 3: Fair Value Measurements
The Company measures certain financial assets and liabilities at fair value on a recurring basis, including money market securities, trading fixed income and equity securities held in its deferred compensation plan and the liability associated with its deferred compensation plan. There were no transfers between fair value measurement levels during the three months ended March 29, 2024 and March 31, 2023. Any transfers between fair value measurement levels would be recorded on the actual date of the event or change in circumstances that caused the transfer.
|
|
Fair Value Measurements at Reporting Date Using |
|
|||||||||||||
|
|
Total |
|
|
Quoted |
|
|
Significant |
|
|
Significant |
|
||||
Assets |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Money market securities (1) |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Fixed income trading securities held in deferred |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Equity trading securities held in deferred compensation |
|
|
|
|
$ |
|
|
|
|
|
|
|
||||
Total |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Deferred compensation plan (3) |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
(1)
(2)
(3)
The fair value of these certain financial assets and liabilities was determined using the following inputs at December 29, 2023 (in thousands):
|
|
Fair Value Measurements at Reporting Date Using |
|
|||||||||||||
|
|
Total |
|
|
Quoted |
|
|
Significant |
|
|
Significant |
|
||||
Assets |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Money market securities (1) |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Fixed income trading securities held in deferred |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Equity trading securities held in deferred compensation |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Deferred compensation plan (3) |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
(1)
- 10 -
(2)
(3)
Money market securities as of March 29, 2024 and December 29, 2023 represent obligations of the United States Treasury. Fixed income and equity trading securities represent mutual funds held in the Company’s deferred compensation plan. See Note 6 for additional information about the Company’s deferred compensation plan.
Cash and cash equivalents consisted of the following as of March 29, 2024 (in thousands):
|
|
|
|
|
Gross |
|
|
Gross |
|
|
|
|
||||
|
|
Amortized |
|
|
Unrealized |
|
|
Unrealized |
|
|
Estimated |
|
||||
|
|
Cost |
|
|
Gains |
|
|
Losses |
|
|
Fair Value |
|
||||
Classified as current assets: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Cash equivalents: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Money market securities |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total cash equivalents |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total cash and cash equivalents |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Cash and cash equivalents consisted of the following as of December 29, 2023 (in thousands):
|
|
Amortized |
|
|
Unrealized |
|
|
Unrealized |
|
|
Estimated |
|
||||
|
|
Cost |
|
|
Gains |
|
|
Losses |
|
|
Fair Value |
|
||||
Classified as current assets: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Cash |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Cash equivalents: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Money market securities |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total cash equivalents |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total cash and cash equivalents |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
At March 29, 2024 and December 29, 2023, the Company did not have any assets or liabilities valued using significant unobservable inputs.
The following financial instruments are not measured at fair value on the Company's unaudited condensed consolidated balance sheet at March 29, 2024 and December 29, 2023, but require disclosure of their fair values: accounts receivable, other assets and accounts payable. The estimated fair value of such instruments at March 29, 2024 and December 29, 2023 approximates their carrying value as reported on the Company’s unaudited condensed consolidated balance sheets.
- 11 -
Note 4: Net Income Per Share
Basic per share amounts are computed using the weighted-average number of shares of common stock outstanding during the period. Diluted per share amounts are calculated using the weighted-average number of shares of common stock outstanding during the period and, when dilutive, the weighted-average number of potential shares of common stock from the issuance of common stock to satisfy outstanding restricted stock units and the exercise of outstanding options to purchase common stock using the treasury stock method.
The following schedule reconciles the shares used to calculate basic and diluted net income per share:
|
|
Three Months Ended |
|
|||||
(In thousands) |
|
March 29, |
|
|
March 31, |
|
||
Shares used in basic per share computation |
|
|
|
|
|
|
||
Effect of dilutive common stock options |
|
|
|
|
|
|
||
Effect of dilutive restricted stock units |
|
|
|
|
|
|
||
Shares used in diluted per share |
|
|
|
|
|
|
||
Common stock options to purchase
Note 5: Stock-Based Compensation
Restricted Stock Units
Restricted stock unit grants are designed to attract and retain employees, and to better align employee interests with those of the Company’s stockholders. For a select group of employees, up to
The value of these restricted stock unit awards is determined based on the market price of the Company’s common stock on the date of grant. The value of fully vested restricted stock unit awards issued is recorded as a reduction to accrued bonuses. The portion of bonus expense that the Company expects to settle with fully vested restricted stock unit awards is recorded as stock-based compensation during the period the bonus is earned. The Company recorded stock-based compensation expense associated with accrued bonus awards of $
- 12 -
stock-based compensation expense associated with the unvested restricted stock unit awards of $
Stock Options
Stock options are granted for terms of
The Company uses the Black-Scholes option-pricing model to determine the fair value of options granted. The determination of the fair value of stock option awards on the date of grant using an option-pricing model is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables. These variables include expected stock price volatility over the term of the award, actual and projected employee stock option exercise behaviors, the risk-free interest rate and expected dividends.
The Company used historical exercise, forfeiture, and post-vesting expiration data to estimate the expected term of options granted. The historical volatility of the Company’s common stock over a period of time equal to the expected term of the options granted was used to estimate expected volatility. The risk-free interest rate used in the option-pricing model was based on United States Treasury zero-coupon issues with remaining terms similar to the expected term of the options. The dividend yield assumption considers the expectation of continued declaration of dividends, offset by option holders’ dividend equivalent rights.
The Company accounts for forfeitures of stock-based awards when they occur. All stock-based payment awards are recognized on a straight-line basis over the requisite service periods of the awards.
- 13 -
Note 6: Deferred Compensation Plans
The Company maintains nonqualified deferred compensation plans for the benefit of a select group of highly compensated employees. Under these plans, participants may elect to defer up to
As of March 29, 2024 and December 29, 2023, vested amounts due under the plans totaled $
Note 7: Supplemental Cash Flow Information
The following is supplemental disclosure of cash flow information:
|
|
Three Months Ended |
|
|||||
(In thousands) |
|
March 29, |
|
|
March 31, |
|
||
Cash paid during period: |
|
|
|
|
|
|
||
Income taxes |
|
$ |
|
|
$ |
|
||
Non-cash investing and financing activities: |
|
|
|
|
|
|
||
Vested stock unit awards issued to settle accrued bonuses |
|
$ |
|
|
$ |
|
||
Accrual for capital expenditures |
|
$ |
|
|
$ |
|
||
Right-of-use asset obtained in exchange for operating lease obligations |
|
$ |
|
|
$ |
|
||
Note 8: Accounts Receivable, Net
At March 29, 2024 and December 29, 2023, accounts receivable, net, was comprised of the following:
|
|
March 29, |
|
|
December 29, |
|
||
(In thousands) |
|
2024 |
|
|
2023 |
|
||
Billed accounts receivable |
|
$ |
|
|
$ |
|
||
Unbilled accounts receivable |
|
|
|
|
|
|
||
Allowance for contract losses and doubtful accounts |
|
|
( |
) |
|
|
( |
) |
Total accounts receivable, net |
|
$ |
|
|
$ |
|
||
The Company maintains allowances for estimated losses over the remaining contractual life of its receivables resulting from the inability of customers to meet their financial obligations or for disputes that affect the Company’s ability to fully collect amounts due. In circumstances where the Company is aware of a specific customer’s inability to meet its financial obligations or aware of a dispute with a specific customer, a specific allowance is recorded to reduce the net recognized receivable to the amount the Company reasonably believes will be collected. For all other customers the Company recognizes allowances for doubtful accounts based upon historical write-offs, customer concentration, customer creditworthiness, current economic conditions, aging of amounts due and future expectations.
- 14 -
A reconciliation of the beginning and ending amount of the allowance for contract losses and doubtful accounts is as follows (in thousands):
Balance at December 29, 2023 |
|
$ |
|
|
Provision for contract losses and doubtful accounts |
|
|
|
|
Write-offs |
|
|
( |
) |
Balance at March 29, 2024 |
|
$ |
|
Note 9: Segment Reporting
The Company has
Segment information for the three months ended March 29, 2024 and March 31, 2023 follows:
Revenues
|
|
Three Months Ended |
|
|||||
(In thousands) |
|
March 29, |
|
|
March 31, |
|
||
Engineering and Other Scientific |
|
$ |
|
|
$ |
|
||
Environmental and Health |
|
|
|
|
|
|
||
Total revenues |
|
$ |
|
|
$ |
|
||
Operating Income
|
|
Three Months Ended |
|
|||||
(In thousands) |
|
March 29, |
|
|
March 31, |
|
||
Engineering and Other Scientific |
|
$ |
|
|
$ |
|
||
Environmental and Health |
|
|
|
|
|
|
||
Total segment operating income |
|
|
|
|
|
|
||
Corporate operating expense |
|
|
( |
) |
|
|
( |
) |
Total operating income |
|
$ |
|
|
$ |
|
||
Certain operating expenses are excluded from the Company’s measure of segment operating income. These expenses include costs associated with its human resources, finance, information technology, and business development groups; the deferred compensation expense/benefit due to the change in value of assets associated with its deferred compensation plan; stock-based compensation associated with restricted stock unit and stock option awards; and the change in its allowance for contract losses and doubtful accounts.
- 15 -
Capital Expenditures
|
|
Three Months Ended |
|
|||||
(In thousands) |
|
March 29, |
|
|
March 31, |
|
||
Engineering and Other Scientific |
|
$ |
|
|
$ |
|
||
Environmental and Health |
|
|
|
|
|
|
||
Total segment capital expenditures |
|
|
|
|
|
|
||
Corporate capital expenditures |
|
|
|
|
|
|
||
Total capital expenditures |
|
$ |
|
|
$ |
|
||
Certain capital expenditures associated with the Company’s corporate cost centers and the related depreciation are excluded from the Company’s segment information.
Depreciation and Amortization
|
|
Three Months Ended |
|
|||||
(In thousands) |
|
March 29, |
|
|
March 31, |
|
||
Engineering and Other Scientific |
|
$ |
|
|
$ |
|
||
Environmental and Health |
|
|
|
|
|
|
||
Total segment depreciation and amortization |
|
|
|
|
|
|
||
Corporate depreciation and amortization |
|
|
|
|
|
|
||
Total depreciation and amortization |
|
$ |
|
|
$ |
|
||
Note 10: Leases
The Company determines if an arrangement is a lease at the inception of the arrangement. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities, and long-term operating lease liabilities in the Company’s condensed consolidated balance sheet. The Company does not have any finance leases as of March 29, 2024.
ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate, based on the information available at commencement date, in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The amortization of operating lease ROU assets and the change in operating lease liabilities is disclosed as a single line item in the condensed consolidated statements of cash flows.
The Company leases office, laboratory, and storage space in
- 16 -
The Company has a Test and Engineering Center on
The Company’s equipment leases are included in the ROU asset and liability balances, but are not material.
The Company leases excess space in its Silicon Valley and Natick facilities. Rental income of $
The components of lease expense included in other operating expenses on the condensed consolidated statements of income were as follows:
|
|
Three Months Ended |
|
|
Three Months Ended |
|
||
(In thousands) |
|
March 29, |
|
|
March 31, |
|
||
Operating lease cost |
|
$ |
|
|
$ |
|
||
Variable lease cost |
|
|
|
|
|
|
||
Short-term lease cost |
|
|
|
|
|
|
||
Supplemental cash flow information related to operating leases was as follows:
|
|
Three Months Ended |
|
|
Three Months Ended |
|
||
(In thousands) |
|
March 29, |
|
|
March 31, |
|
||
Cash paid for amounts included in the measurement of operating |
|
$ |
|
|
$ |
|
||
Supplemental balance sheet information related to operating leases was as follows:
|
March 29, |
|
March 31, 2023 |
Weighted Average Remaining Lease Term |
|
||
Weighted Average Discount Rate |
|
Maturities of operating lease liabilities as of March 29, 2024:
(In thousands) |
|
Operating Leases |
|
|
2024 (excluding the three months ended March 29, 2024) |
|
|
|
|
2025 |
|
|
|
|
2026 |
|
|
|
|
2027 |
|
|
|
|
2028 |
|
|
|
|
Thereafter |
|
|
|
|
Total lease payments |
|
$ |
|
|
Less imputed interest |
|
|
( |
) |
Total lease liability |
|
$ |
|
|
Note 11: Contingencies
The Company is a party to various legal actions from time to time and may be contingently liable in connection with claims and contracts arising in the normal course of business, the outcome of which the Company believes, after consultation with legal counsel, will not have a material adverse effect on its financial condition, results
- 17 -
of operations or liquidity. However, due to the risks and uncertainties inherent in legal proceedings, actual results could differ from current expected results. All legal costs associated with litigation are expensed as incurred.
Note 12: Subsequent Events
On
- 18 -
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion should be read in conjunction with the unaudited condensed consolidated financial statements and notes thereto included herein and with our audited consolidated financial statements and notes thereto for the fiscal year ended December 29, 2023, which are contained in our fiscal 2023 Annual Report on Form 10-K, which was filed with the U.S. Securities and Exchange Commission on February 23, 2024 (our “2023 Annual Report”).
Forward-Looking Statements
This Quarterly Report on Form 10-Q contains certain “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995, and the rules promulgated pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended) that are based on the beliefs of our management, as well as assumptions made by and information currently available to our management. Such forward-looking statements are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. When used in this document, the words “intend,” “anticipate,” “believe,” “estimate,” “expect” and similar expressions, as they relate to us or our management, identify such forward-looking statements. Such statements reflect the current views of us or our management with respect to future events and are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual results, performance, or achievements could differ materially from those expressed in, or implied by, any such forward-looking statements. Factors that could cause or contribute to such material differences include the possibility that the demand for our services may decline as a result of changes in general and industry specific economic conditions, the timing of engagements for our services, the effects of competitive services and pricing, the absence of backlog related to our business, our ability to attract and retain key employees, the effect of tort reform and government regulation on our business and liabilities resulting from claims made against us. Additional risks and uncertainties are discussed in our 2023 Annual Report under the heading “Risk Factors” and elsewhere in this report. The inclusion of such forward-looking information should not be regarded as a representation by the us or any other person that the future events, plans, or expectations we contemplated will be achieved. Due to such uncertainties and risks, you are warned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. We do not intend to release publicly any updates or revisions to any such forward-looking statements.
Business Overview
Exponent, Inc., is an engineering and scientific consulting firm that provides solutions to complex problems. Our multidisciplinary team of scientists, engineers and business consultants brings together more than 90 different technical disciplines to solve complicated issues facing industry and business today. Our services include analysis of product development, product recall, regulatory compliance, and the discovery of potential problems related to products, people, property and impending litigation.
CRITICAL ACCOUNTING ESTIMATES
There have been no significant changes in our critical accounting estimates during the three months ended March 29, 2024, as compared to the critical accounting estimates disclosed in Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our 2023 Annual Report.
RESULTS OF CONSOLIDATED OPERATIONS
Executive Summary
Revenues for the first quarter of 2024 increased 3% to $144,933,000 as compared to $140,309,000 during the same period last year. Revenues before reimbursements for the first quarter of 2024 increased 7% to $137,207,000 as compared to $128,705,000 during the same period last year.
Growth during the first quarter of 2024 was driven by our reactive work. We performed robust failure analysis and dispute-related work across a wide spectrum of industries. From wind farms to life saving medical devices, clients around the world continue to rely on Exponent’s unrivalled failure analysis expertise to provide critical, real-time insights on regulatory and safety related decisions. Exponent’s team of experts continues to advise
- 19 -
clients on critical needs throughout the product lifecycle. Our proactive business, excluding consumer electronics which continues to experience cyclical impacts, increased year over year driven by strength in the transportation and energy sectors. The increasing global attention on safety, health, and environmental concerns coupled with the complexity and pace of innovation continues to drive a greater demand for our expertise. Exponent remains well positioned to serve our clients and deliver mission-critical insights for the present while paving the way for future innovations.
Net income increased 3% to $30,142,000 during the first quarter of 2024 as compared to $29,124,000 during the same period last year. Diluted earnings per share increased to $0.59 per share during the first quarter of 2024 as compared to $0.56 during the same period last year. The excess tax benefit associated with stock-based awards decreased to $946,000 during the first quarter of 2024 as compared to $3,627,000 during the first quarter of 2023. The decrease in the excess tax benefit was due to a smaller increase in the value of our common stock between the grant date and the release date for the restricted stock units released during the first quarter of 2024 as compared to the first quarter of 2023.
We remain focused on selectively adding top talent and developing the skills necessary to expand our market position and providing clients with in-depth scientific research and analysis to determine what happened and how to prevent failures or exposures in the future. We also remain focused on capitalizing on emerging growth areas, managing other operating expenses, generating cash from operations, maintaining a strong balance sheet and undertaking activities such as share repurchases and dividends to enhance shareholder value.
Overview of the Three Months Ended March 29, 2024
During the first quarter of 2024, billable hours increased 2% to 392,000 as compared to 385,000 during the same period last year. Our utilization increased to 75% during the first quarter of 2024 as compared to 70% during the same period last year. Technical full-time equivalent employees decreased 5% to 1,003 during the first quarter of 2024 as compared to 1,052 during the same period last year. We expect a small sequential decline in average technical full-time equivalent employees during the second quarter of 2024. We expect sequential headcount growth during the second half of 2024 as we continue to selectively hire key talent to expand our capabilities.
Three Months Ended March 29, 2024 compared to Three Months Ended March 31, 2023
Revenues
|
|
Three Months Ended |
|
|
|
|
||||||
(in thousands, except percentages) |
|
March 29, |
|
|
March 31, |
|
|
Percent |
|
|||
Engineering and Other Scientific |
|
$ |
121,471 |
|
|
$ |
117,048 |
|
|
|
3.8 |
% |
Percentage of total revenues |
|
|
83.8 |
% |
|
|
83.4 |
% |
|
|
|
|
Environmental and Health |
|
|
23,462 |
|
|
|
23,261 |
|
|
|
0.9 |
% |
Percentage of total revenues |
|
|
16.2 |
% |
|
|
16.6 |
% |
|
|
|
|
Total revenues |
|
$ |
144,933 |
|
|
$ |
140,309 |
|
|
|
3.3 |
% |
The increase in revenues for our Engineering and Other Scientific segment was due to an increase in billable hours and an increase in billing rates. During the first quarter of 2024, billable hours for this segment increased by 3% to 315,000 as compared to 306,000 during the same period last year. The increase in billable hours was driven by continued strong demand for our services from the energy, vehicle and medical device industries. Utilization for this segment increased to 77% during the first quarter of 2024 as compared to 72% during the same period last year. Technical full-time equivalent employees in this segment decreased 4% to 785 during the first quarter of 2024 as compared to 819 for the same period last year.
The increase in revenues for our Environmental and Health segment was due to an increase in billing rates partially offset by a decrease in billable hours. During the first quarter of 2024, billable hours for this segment decreased by 3% to 77,000 as compared to 79,000 during the same period last year. Utilization in this segment increased to 68% during the first quarter of 2024 as compared to 66% during the same period last year. Work in this segment was primarily driven by our regulatory consulting in chemical industry. Technical full-time equivalent
- 20 -
employees in this segment decreased 6% to 218 during the first quarter of 2024 as compared to 233 during the same period last year.
Compensation and Related Expenses
|
|
Three Months Ended |
|
|
|
|
||||||
(in thousands, except percentages) |
|
March 29, |
|
|
March 31, |
|
|
Percent |
|
|||
Compensation and related expenses |
|
$ |
90,327 |
|
|
$ |
84,181 |
|
|
|
7.3 |
% |
Percentage of total revenues |
|
|
62.3 |
% |
|
|
60.0 |
% |
|
|
|
|
The increase in compensation and related expenses during the first quarter of 2024 was due to a change in the value of assets associated with our deferred compensation plan, an increase in payroll expense, an increase in fringe benefits, and an increase in bonus expense. During the first quarter of 2024, deferred compensation expense increased by $2,349,000 with a corresponding increase to other income, net, as compared to the same period last year, due to the change in value of assets associated with our deferred compensation plan. This increase consisted of an increase in the value of plan assets of $6,267,000 during the first quarter of 2024 as compared to an increase in the value of plan assets of 3,918,000 during the same period last year. Payroll expense increased by $1,955,000 and fringe benefits increased by $928,000 during the first quarter of 2024 due to our annual salary adjustments. During the first quarter of 2024, bonus expense increased by $1,114,000 due to a corresponding increase in income before income taxes, before bonus expense and before stock-based compensation. We expect our compensation expense, excluding the change in value of deferred compensation plan assets, to increase as we selectively add new talent and adjust compensation to market conditions.
Other Operating Expenses
|
|
Three Months Ended |
|
|
|
|
||||||
(in thousands, except percentages) |
|
March 29, |
|
|
March 31, |
|
|
Percent |
|
|||
Other operating expenses |
|
$ |
10,531 |
|
|
$ |
9,561 |
|
|
|
10.1 |
% |
Percentage of total revenues |
|
|
7.3 |
% |
|
|
6.8 |
% |
|
|
|
|
Other operating expenses include facilities-related costs, technical materials, computer-related expenses and depreciation and amortization of property, equipment and leasehold improvements. The increase in other operating expenses during the first quarter of 2024 was primarily due to an increase in occupancy expense of $477,000 and an increase in depreciation and amortization expense of $336,000. The increases in occupancy expenses and depreciation and amortization were due to continued investment in our corporate infrastructure. During the second quarter of 2024 we expect to extend our land lease with the State of Arizona to January of 2043, resulting in an additional non-cash rent expense of $360,000 in the second quarter of 2024 and $1,080,000 in each of the third and fourth quarters of 2024. This increased level of rent expense will continue through the extended lease term with adjustments in 2033 and 2038 based on the consumer price index. We also expect other operating expenses to grow as we selectively add new talent and make investments in our corporate infrastructure.
Reimbursable Expenses
|
|
Three Months Ended |
|
|
|
|
||||||
(in thousands, except percentages) |
|
March 29, |
|
|
March 31, |
|
|
Percent |
|
|||
Reimbursable expenses |
|
$ |
7,726 |
|
|
$ |
11,604 |
|
|
|
-33.4 |
% |
Percentage of total revenues |
|
|
5.3 |
% |
|
|
8.3 |
% |
|
|
|
|
- 21 -
The amount of reimbursable expenses will vary from quarter to quarter depending on the nature of our projects. The decrease in reimbursable expenses during the first quarter of 2024 was due to a decrease in proactive projects for the consumer electronics sector.
General and Administrative Expenses
|
|
Three Months Ended |
|
|
|
|
||||||
(in thousands, except percentages) |
|
March 29, |
|
|
March 31, |
|
|
Percent |
|
|||
General and administrative expenses |
|
$ |
5,636 |
|
|
$ |
5,843 |
|
|
|
-3.5 |
% |
Percentage of total revenues |
|
|
3.9 |
% |
|
|
4.2 |
% |
|
|
|
|
The decrease in general and administrative expenses was primarily due to a decrease in recruiting expenses of $212,000. The decrease in recruiting expenses was due to a decrease in recruiting activity associated with our efforts to align resources with demand. We expect general and administrative expenses to increase as we selectively add new talent and expand our business development and staff development initiatives.
Operating Income
|
|
Three Months Ended |
|
|
|
|
||||||
(In thousands) |
|
March 29, |
|
|
March 31, |
|
|
Percent |
|
|||
Engineering and Other Scientific |
|
$ |
48,631 |
|
|
$ |
43,619 |
|
|
|
11.5 |
% |
Environmental and Health |
|
|
8,236 |
|
|
|
7,554 |
|
|
|
9.0 |
% |
Total segment operating income |
|
|
56,867 |
|
|
|
51,173 |
|
|
|
11.1 |
% |
Corporate operating expense |
|
|
(26,154 |
) |
|
|
(22,053 |
) |
|
|
18.6 |
% |
Total operating income |
|
$ |
30,713 |
|
|
$ |
29,120 |
|
|
|
5.5 |
% |
The increase in operating income for our Engineering and Other Scientific Segment during the first quarter of 2024 as compared to the same period last year was due to an increase in revenues. The increase in revenues was due to an increase in billable hours and an increase in billing rates. Growth during the first quarter of 2024 was driven by continued strong demand for our services across the energy, vehicle and medical device sectors.
The increase in operating income for our Environmental and Health segment during the first quarter of 2024 was driven by our regulatory consulting in the chemical industry.
Certain operating expenses are excluded from our measure of segment operating income. These expenses include the costs associated with our human resources, finance, information technology, and business development groups; the deferred compensation expense/benefit due to the change in value of assets associated with our deferred compensation plan; stock-based compensation associated with restricted stock unit and stock option awards; and the change in our allowance for contract losses and doubtful accounts.
The increase in corporate operating expenses during the first quarter of 2024 as compared to the same period last year was primarily due to an increase in deferred compensation expense and an increase in the costs associated with our human resources, finance, information technology and business development groups. During the first quarter of 2024, deferred compensation expense increased $2,349,000, with a corresponding increase to other income, net, as compared to the same period last year, due to the change in value of assets associated with our deferred compensation plan. This increase consisted of an increase in the value of plan assets of $6,267,000 during the first quarter of 2024 as compared to an increase in the value of plan assets of $3,918,000 during the same period last year.
Other Income, Net
|
|
Three Months Ended |
|
|
|
|
||||||
(in thousands, except percentages) |
|
March 29, |
|
|
March 31, |
|
|
Percent |
|
|||
Other income / (loss), net |
|
$ |
9,710 |
|
|
$ |
6,418 |
|
|
|
51.3 |
% |
Percentage of total revenues |
|
|
6.7 |
% |
|
|
4.6 |
% |
|
|
|
|
- 22 -
Other income, net, consists primarily of changes in the value of assets associated with our deferred compensation plan, interest income earned on available cash, cash equivalents and short-term investments, and rental income from leasing space in our Silicon Valley and Natick facilities. The increase in other income, net, was primarily due to a change in the value of assets associated with our deferred compensation plan and an increase in interest income. During the first quarter of 2024, other income, net, increased by $2,349,000 with a corresponding increase to deferred compensation expense, as compared to the same period last year, due to a change in the value of assets associated with our deferred compensation plan. This increase consisted of an increase in the value of the plan assets of $6,267,000 during the first quarter of 2024 as compared to an increase in the value of the plan assets of $3,918,000 during the same period last year. During the first quarter of 2024 interest income increased by $856,000 due to higher interest rates.
Income Taxes
|
|
Three Months Ended |
|
|
|
|
||||||
(in thousands, except percentages) |
|
March 29, |
|
|
March 31, |
|
|
Percent |
|
|||
Income taxes |
|
$ |
10,281 |
|
|
$ |
6,414 |
|
|
|
60.3 |
% |
Percentage of total revenues |
|
|
7.1 |
% |
|
|
4.6 |
% |
|
|
|
|
Effective tax rate |
|
|
25.4 |
% |
|
|
18.0 |
% |
|
|
|
|
The excess tax benefit associated with stock-based awards was $946,000 during the first quarter of 2024 as compared to $3,627,000 during the same period last year. The decrease in the excess tax benefit was due to a smaller increase in the value of our common stock between the grant date and the release date for the restricted stock units released during the first quarter of 2024 as compared to the first quarter of 2023. Excluding the impact of the excess tax benefit, the effective tax rate would have been 27.8% during the first quarter of 2024 as compared to 28.3% during the same period last year.
LIQUIDITY AND CAPITAL RESOURCES
We believe our existing balances of cash, cash equivalents, short-term investments and cash generated from operations will be sufficient to satisfy our working capital needs, capital expenditures, outstanding commitments, stock repurchases, dividends and other liquidity requirements over at least the next twelve months.
|
|
Three Months Ended |
|
|||||
(in thousands) |
|
March 29, |
|
|
March 31, |
|
||
Net cash provided by (used in) operating activities |
|
$ |
10,432 |
|
|
$ |
(6,703 |
) |
Net cash used in investing activities |
|
|
(1,482 |
) |
|
|
(5,668 |
) |
Net cash used in financing activities |
|
|
(27,227 |
) |
|
|
(23,740 |
) |
We financed our business during the first three months of 2024 through available cash. As of March 29, 2024, our cash and cash equivalents were $168,665,000 as compared to $187,150,000 at December 29, 2023.
Generally, our net cash provided by operating activities is used to fund our day to day operating activities. First quarter operating cash requirements are generally higher due to payment in the first quarter of our annual bonuses accrued during the prior year. Our largest source of operating cash flows is collections from our clients. Our primary uses of cash from operating activities are for employee related expenditures, leased facilities, taxes, and general operating expenses including marketing and travel.
The decrease in net cash used in investing activities during the first three months of 2024, as compared to the same period last year, was due to a decrease in capital expenditures. The decrease in capital expenditures was due to a decrease in investment in our corporate infrastructure.
- 23 -
The increase in net cash used in financing activities during the first three months of 2024, as compared to the same period last year, was due to an increase in repurchases of our common stock and an increase in dividends partially offset by a decrease in payroll taxes for restricted stock units.
We expect to continue our investing activities, including capital expenditures. Furthermore, cash reserves may be used to repurchase shares of common stock under our stock repurchase programs, pay dividends, or strategically acquire professional service firms that are complementary to our business. We expect to finalize a 15- year extension of our land lease with the state of Arizona during the second quarter of 2024. Payments under the lease are currently $1 million per year and will continue at that level until the expiration of the current lease in January of 2028. We expect annual rent payments of $6.2 million during the extended term of the lease beginning in 2028 with adjustments in 2033 and 2038 based on the consumer price index. We are currently finalizing negotiations with the lessor, and as of the date of this filing the lease extension has not been executed.
We maintain a nonqualified deferred compensation plan for the benefit of a select group of highly compensated employees. Vested amounts due under the plan of $116,005,000 were recorded as a long-term liability on our unaudited condensed consolidated balance sheet at March 29, 2024. Vested amounts due under the plan of $13,134,000 were recorded as a current liability on our unaudited condensed consolidated balance sheet at March 29, 2024. Our assets that are earmarked to pay benefits under the plan are held in a rabbi trust and are subject to the claims of our creditors. As of March 29, 2024, invested amounts under the plan of $113,844,000 were recorded as a long-term asset on our unaudited condensed consolidated balance sheet. As of March 29, 2024, invested amounts under the plan of $14,291,000 were recorded as a current asset on our unaudited condensed consolidated balance sheet.
As permitted under Delaware law, we have agreements whereby we indemnify our officers and directors for certain events or occurrences while the officer or director is, or was, serving at our request in such capacity. The indemnification period covers all pertinent events and occurrences during the officer’s or director’s lifetime. The maximum potential amount of future payments we could be required to make under these indemnification agreements is unlimited; however, we have director and officer insurance coverage that reduces our exposure and enables us to recover a portion of any future amounts paid.
Non-GAAP Financial Measures
Regulation G, Conditions for Use of Non-Generally Accepted Accounting Principles ("Non-GAAP") Financial Measures, and other U.S. Securities and Exchange Commission (“SEC”) rules and regulations define and prescribe the conditions for use of Non-GAAP financial information. Generally, a Non-GAAP financial measure is a numerical measure of a company's performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. We closely monitor two financial measures, EBITDA and EBITDAS, which meet the definition of Non-GAAP financial measures. We define EBITDA as net income before income taxes, net interest income, depreciation and amortization. We define EBITDAS as EBITDA before stock-based compensation. The Company regards EBITDA and EBITDAS as useful measures of operating performance to complement operating income, net income and other GAAP financial performance measures. Additionally, management believes that EBITDA and EBITDAS provide meaningful comparisons of past, present and future operating results. These measures are used to evaluate our financial results, develop budgets and determine employee compensation. These measures, however, should be considered in addition to, and not as a substitute for or superior to, operating income, cash flows, or other measures of financial performance prepared in accordance with GAAP. A reconciliation of the Non-GAAP measures to the nearest comparable GAAP measure is set forth below.
The following table shows EBITDA (determined as shown in the reconciliation table below) as a percentage of revenues before reimbursements for the three months ended March 29, 2024 and March 31, 2023:
|
|
Three Months Ended |
|
|||||
(in thousands, except percentages) |
|
March 29, |
|
|
March 31, |
|
||
Revenues before reimbursements |
|
$ |
137,207 |
|
|
$ |
128,705 |
|
EBITDA |
|
$ |
40,121 |
|
|
$ |
35,756 |
|
EBITDA as a % of revenues before |
|
|
29.2 |
% |
|
|
27.8 |
% |
- 24 -
The increase in EBITDA as a percentage of revenues before reimbursements, during the first quarter of 2024 as compared to the same period last year, was primarily due to an increase in utilization and a decrease in general and administrative expenses. Our utilization increased to 75% during the first quarter of 2024 as compared to 70% during the same period last year. The increase in utilization was due to strong business activity for our reactive service offerings and our successful efforts to align resources with demand. The decrease in general and administrative expenses was due to a decrease in recruiting expenses due to the decrease in technical full-time equivalent employees.
The following table is a reconciliation of EBITDA and EBITDAS to the most comparable GAAP measure, net income, for the three months ended March 29, 2024 and March 31, 2023:
|
|
Three Months Ended |
|
|||||
(in thousands) |
|
March 29, |
|
|
March 31, |
|
||
Net income |
|
$ |
30,142 |
|
|
$ |
29,124 |
|
Add back (subtract): |
|
|
|
|
|
|
||
Income taxes |
|
|
10,281 |
|
|
|
6,414 |
|
Interest income, net |
|
|
(2,626 |
) |
|
|
(1,770 |
) |
Depreciation and amortization |
|
|
2,324 |
|
|
|
1,988 |
|
EBITDA |
|
|
40,121 |
|
|
|
35,756 |
|
Stock-based compensation |
|
|
7,340 |
|
|
|
7,063 |
|
EBITDAS |
|
$ |
47,461 |
|
|
$ |
42,819 |
|
- 25 -
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to interest rate risk associated with our balances of cash and cash equivalents. We manage our interest rate risk by maintaining an investment portfolio primarily consisting of debt instruments with high credit quality and relatively short average effective maturities in accordance with our investment policy. The maximum effective maturity of any issue in our portfolio is 3 years and the maximum average effective maturity of the portfolio cannot exceed 12 months. If interest rates were to instantaneously increase or decrease by 100 basis points, the change in the fair market value of our portfolio of cash equivalents would not have a material impact on our financial statements. We do not use derivative financial instruments in our portfolio. There have not been any material changes during the period covered by this Quarterly Report on Form 10-Q to our interest rate risk exposures, or how these exposures are managed. Notwithstanding our efforts to manage interest rate risk, there can be no assurances that we will be adequately protected against the risks associated with interest rate fluctuations.
We have foreign currency risk related to our revenues and expenses denominated in currencies other than the U.S. dollar, primarily the British Pound, the Euro, the Chinese Yuan, and the Hong Kong Dollar. Accordingly, changes in exchange rates may negatively affect the revenues and net income of our foreign subsidiaries as expressed in U.S. dollars.
At March 29, 2024, we had net assets of approximately $16.6 million with a functional currency of the British Pound, net assets of approximately $4.3 million with a functional currency of the Hong Kong Dollar, net assets of approximately $2.9 million with a functional currency of the Singapore Dollar, and net assets of approximately $1.5 million with a functional currency of the Chinese Yuan associated with our operations in the United Kingdom, China, Hong Kong and Singapore, respectively.
We also have foreign currency risk related to foreign currency transactions and monetary assets and liabilities denominated in currencies that are not the functional currency. We have experienced and will continue to experience fluctuations in our net income as a result of gains (losses) on these foreign currency transactions and the remeasurement of monetary assets and liabilities. At March 29, 2024, we had net assets denominated in the non-functional currency of approximately $9.2 million.
We do not use foreign exchange contracts to hedge any foreign currency exposures. To date, the impacts of foreign currency exchange rate changes on our consolidated revenues and consolidated net income have not been significant. However, our continued international growth increases our exposure to exchange rate fluctuations and as a result such fluctuations could have a significant impact on our future results of operations.
Item 4. Controls and Procedures
(a) Evaluation of Disclosure Controls and Procedures
As required by Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended, an evaluation was performed under the supervision and with the participation of the Company’s management, including the Chief Executive Officer and the Chief Financial Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this quarterly report. Based on that evaluation, the Company’s management, including the Chief Executive Officer and the Chief Financial Officer, concluded that, as of March 29, 2024, the Company’s disclosure controls and procedures were effective.
We review and evaluate the design and effectiveness of our disclosure controls and procedures on an ongoing basis, to improve our controls and procedures over time and to correct any deficiencies that we may discover in the future. Our goal is to ensure that our senior management has timely access to all material financial and non-financial information concerning our business. While we believe the present design of our disclosure controls and procedures is effective to achieve our goal, future events affecting our business may cause us to significantly modify our disclosure controls and procedures.
(b) Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting during the three-month period ended March 29, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
- 26 -
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
Exponent is not engaged in any material legal proceedings.
Item 1A. Risk Factors
There have been no material changes from risk factors as previously discussed under the heading “Risk Factors” in the Company’s 2023 Annual Report.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
The following table provides information on the Company’s repurchases of the Company’s common stock for the three months ended March 29, 2024 (in thousands, except price per share):
|
|
Total |
|
|
Average |
|
|
Total |
|
|
Approximate |
|
||||
December 30 to January 26 |
|
|
- |
|
|
$ |
- |
|
|
|
- |
|
|
$ |
38,390 |
|
January 27 to February 23 |
|
|
10 |
|
|
|
73.62 |
|
|
|
10 |
|
|
|
99,290 |
|
February 24 to March 29 |
|
|
61 |
|
|
|
77.69 |
|
|
|
61 |
|
|
|
94,534 |
|
Total |
|
|
71 |
|
|
|
77.13 |
|
|
|
71 |
|
|
$ |
94,534 |
|
Repurchases of the Company’s common stock were affected pursuant to a repurchase program authorized by the Company’s Board of Directors.
Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
Rule 10b5-1 Plans
The following table summarizes the adoption by the Company’s directors and officers of trading plans intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) during the three months ended March 29, 2024:
- 27 -
Name and Title |
Expiration Date |
Aggregate Number of Securities to be Sold |
Aggregate Number of Securities to be Purchased |
|
0 |
During the three months ended March 29, 2024, no pre-existing trading plans intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) were modified or terminated by the Company’s directors and officers, and no other written trading arrangements that are not intended to qualify for the Rule 10b5-1(c) affirmative defense were
- 28 -
Item 6. Exhibits
31.1 |
|
|
|
31.2 |
|
|
|
32.1 |
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350. |
|
|
32.2 |
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350. |
|
|
101.INS |
Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
|
|
101.SCH |
Inline XBRL Taxonomy Extension Schema Document |
|
|
101.CAL |
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
|
|
101.DEF |
Inline XBRL Taxonomy Extension Definition Linkbase Document |
|
|
101.LAB |
Inline XBRL Taxonomy Extension Label Linkbase Document |
|
|
101.PRE |
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
|
|
Exhibit 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
- 29 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
EXPONENT, INC. |
|
|
(Registrant) |
|
|
|
Date: May 3, 2024 |
|
|
|
|
/s/ Catherine Ford Corrigan |
|
|
Catherine Ford Corrigan, Ph.D., Chief Executive Officer |
|
|
|
|
|
|
|
|
/s/ Richard L. Schlenker |
|
|
Richard L. Schlenker, Chief Financial Officer |
- 30 -